Access To Affordable Healthcare: A Global Wake-Up Call Fosters Coalition Of The Like-Minded 27/11/2017 by Patralekha Chatterjee for Intellectual Property Watch Leave a Comment NEW DELHI — Few topics in the global health agenda are as contentious as access to affordable medicines and medical care, and expectedly, divergent views permeated the discussions at a high-level conference in New Delhi, India last week. But if there is one thing that the three-day meet made amply clear, it was this: access to affordable healthcare has emerged as a global problem, and an emerging coalition of the like-minded, cutting across the developed and developing countries, is determined to have their voices heard in international policy circles on the issue.
EPO: New Employment Rules Roil Staff; Management Responds On Demand For More Productivity 27/11/2017 by Dugie Standeford for Intellectual Property Watch Leave a Comment Outgoing European Patent Office President Benoȋt Battistelli has proposed a new “employment framework” that includes fixed-term contracts for patent examiners, reigniting anger among staff members already in a tense relationship with management. There is also concern that Battistelli’s apparent push – which the EPO denies – for more products (defined as prior art searches and proposals for patent grants) is hurting patent quality.
Medicines Excitement In The Netherlands – New Health Minister Announces Firm Action On “Absurd” Medicines Pricing And Gets The European Medicines Agency 27/11/2017 by Intellectual Property Watch 1 Comment The new Minister of Health of the Netherlands, Bruno Bruins, came in guns blazing when he put the pharmaceutical industry on notice and announced on 22 November to “change the rules of the game” to tackle, what he called “absurd” medicines pricing, writes Ellen ‘t Hoen.
US NAFTA Negotiating Objectives For IP? Go Big On Digital IP Protection, Fend Off GIs 20/11/2017 by Intellectual Property Watch 1 Comment The Office of the United States Trade Representative (USTR) has issued a set of negotiating objectives for renegotiating the 1994 North American Free Trade Agreement (NAFTA) that include its hopes for elevating intellectual property in the trade deal. Included in the list: force Canada and Mexico to ratify international treaties, accept US law on IP protection and create conditions for “strong” IP enforcement especially online, and ensure ample protection for products with generic names. Perhaps oddly, there is only one mention of trade, which includes respect for a 2001 text at the World Trade Organization on IP and public health.
Rise Of Global Value Chains Propels Intangible Capital Revenues, WIPO Report Says 20/11/2017 by Catherine Saez, Intellectual Property Watch Leave a Comment A World Intellectual Property Organization report released today shows the growing global importance of intangible capital and its share in the value of end products. The report does not however provide a geographical repartition of this value, nor who actually owns the returns on intangible capital. Three case studies shed light on different production areas: coffee, smart phones, and solar panels.
TPP Texts Show Suspended IP Provisions 16/11/2017 by William New, Intellectual Property Watch 2 Comments Trade ministers negotiating the Trans-Pacific Partnership agreement have released the list of provisions they have suspended, including a range of articles related to intellectual property rights, such as patentable subject matter, test data protection, biologics, copyright terms of protection, and technological protection measures.
WIPO Vaccines Report Contestable, With UN High-Level Panel Misquoted, Advocate Says 10/11/2017 by Intellectual Property Watch Leave a Comment The World Intellectual Property Organization this week held an event that delved into research, markets and access for vaccines with panels that showed unusual breadth of representation for the UN IP agency. But health advocates have taken issue with the wording of a report released by WIPO at the event.
WIPO Hosts Widely Represented Discussion On Vaccine Innovation And Access 09/11/2017 by Catherine Saez, Intellectual Property Watch 1 Comment A well-represented set of experts this week held discussions on the current situation of access to vaccines, the market, the role of pharmaceutical companies, and partnerships. Vaccines were not a field much affected by patents in the past, but the situation has changed and new vaccines are now covered by intellectual property, which might constitute a barrier to access, according to speakers.
South Centre: Clear Rules Needed On Biosimilars Equivalence To Help Market Entry, Lower Prices 09/11/2017 by Intellectual Property Watch Leave a Comment As soon as 2022, biological drugs made from active protein substances are expected to make up 50 percent of the pharmaceutical market, as they are increasingly used to treat a number of illnesses such as diabetes, cancer and hepatitis. But with the high price of therapeutics and difficulty in producing biologically similar products, and with the originator products now coming off patent, regulation is of high importance, says a new report from the intergovernmental South Centre.
Geneva Buzzing With Ideas And Events For International Entrepreneurship Week 09/11/2017 by Intellectual Property Watch Leave a Comment A weeklong event next week has been co-organised and sponsored by a number of Geneva actors, such as the World Intellectual Property Organization, the European Organization for Nuclear Research (CERN), and the University of Geneva, as well as lesser known groups and projects, to celebrate the international week of entrepreneurship.